CAC Score (Coronary Artery Calcium): What This Test Actually Measures

What the CAC Score Physically Measures

The test detects and quantifies hydroxyapatite calcium deposits embedded in atherosclerotic plaque within the coronary artery walls. It does not measure cholesterol, blood flow, or soft (non-calcified) plaque directly.

A multi-detector CT scanner captures images of the heart synchronized to the electrocardiogram so each frame falls between heartbeats, minimizing motion artifact. Software then identifies any voxel with a density above 130 Hounsfield units (HU) within the anatomic boundaries of the left main, left anterior descending, circumflex, and right coronary arteries [1]. Each calcified lesion is scored using the Agatston method: the area of the lesion (in mm²) is multiplied by a density weighting factor (1 through 4, based on peak HU). The total Agatston score is the sum across all four coronary territories.

Because calcium deposition in the artery wall is a late-stage marker of atherosclerosis, a positive score confirms the presence of coronary artery disease. A score of 0 does not guarantee the absence of soft plaque, but it does carry a very low (<1% per year) event rate in most populations [2].

The scan requires no fasting, no IV contrast, and no exercise. Patients lie still for roughly 10 to 15 minutes while the scanner acquires images during a single breath-hold. Radiation exposure is low, approximately 1 millisievert (mSv), which the American Heart Association considers acceptable for screening purposes [3].

The Agatston Scoring System Explained

Arthur Agatston and Warren Janowitz developed the scoring method in 1990 using electron-beam CT, and it remains the standard three decades later [1]. The system works by assigning each calcified focus a density factor: 1 for 130 to 199 HU, 2 for 200 to 299 HU, 3 for 300 to 399 HU, and 4 for 400 HU or above.

This weighting means that a small but extremely dense deposit can score higher than a larger deposit of lower density. Two patients with identical total plaque volume may receive different Agatston scores if the mineral composition of their plaque differs. The score is reproducible (interscan variability of 15% to 20% in most labs), which is precise enough to separate patients into distinct risk categories but not precise enough to track small year-over-year changes in a single patient [4].

Some centers also report a calcium volume score or a calcium mass score. Volume scoring removes the density weighting and measures total calcified volume in cubic millimeters. Mass scoring uses a calibration phantom to estimate absolute calcium mass. Neither has replaced the Agatston score in clinical guidelines, partly because the massive epidemiologic datasets (MESA, Framingham, Heinz Nixdorf Recall) all used Agatston units [5][6].

What the Score Ranges Mean for Cardiovascular Risk

A CAC score is not interpreted in isolation. It is layered on top of traditional risk calculators, specifically the Pooled Cohort Equations (PCE) used to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk.

Score of 0. The Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814) showed that participants with a CAC of 0 had a 10-year coronary event rate below 1.5%, regardless of the number of traditional risk factors present [5]. A zero score carries a "warranty period" of roughly 5 to 10 years before rescanning is warranted, according to data from Valenti et al. (N=9,715, 14.6-year follow-up) [7]. For patients at borderline risk (PCE 5% to 7.5%), a CAC of 0 supports deferring statin therapy after shared decision-making.

Score of 1 to 99. Mild plaque is present. The 2019 ACC/AHA primary prevention guidelines note that a score in this range, particularly above the 75th percentile for age, sex, and ethnicity, favors initiating statin therapy [8]. MESA data showed a hazard ratio for coronary events of approximately 3.6 compared with a score of 0 [5].

Score of 100 to 299. Moderate plaque burden. The Heinz Nixdorf Recall Study (N=4,487) found that a CAC of 100 or above doubled the rate of hard cardiac events compared with scores of 1 to 99 over a median follow-up of 5 years [6]. Statin therapy and aggressive risk-factor management are generally recommended.

Score of 300 or above. Extensive calcified plaque. The CAC Consortium (N=66,636) reported that scores above 300 were associated with a 10-year all-cause mortality rate of approximately 12% [9]. The 2019 ACC/AHA guidelines describe a CAC of 300 or above (or above the 75th age/sex/ethnicity percentile) as a factor that "favors statin therapy" even in patients whose PCE falls in borderline territory [8].

Dr. Michael Blaha, director of clinical research at the Johns Hopkins Ciccarone Center, has stated: "A coronary calcium score is the most powerful single test we have for predicting future heart attacks in asymptomatic people. It reclassifies risk better than any biomarker, ankle-brachial index, or carotid intima-media thickness measurement" [10].

Who Should Get the Test

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease provides the clearest decision framework [8]. CAC scanning is most useful for adults aged 40 to 75 with a 10-year ASCVD risk of 5% to 20% (borderline to intermediate) who are uncertain about starting a statin. A CAC of 0 may allow deferral. A CAC of 100 or above (or above the 75th percentile) tips the decision toward treatment.

The United States Preventive Services Task Force (USPSTF) issued an "I" statement (insufficient evidence) for CAC screening in its 2018 assessment of cardiovascular risk assessment with nontraditional markers, citing a lack of direct randomized trial evidence linking CAC screening to improved health outcomes [11]. This does not mean the test is inaccurate. It means no randomized controlled trial has yet assigned patients to "CAC-guided therapy" vs. "no CAC" and measured hard endpoints like myocardial infarction.

Populations where CAC testing is not recommended:

• Adults already on statin therapy (treatment may slow calcium progression but does not reduce the score, complicating interpretation)
• Adults with established cardiovascular disease (they already qualify for secondary prevention)
• Low-risk adults (PCE <5%) under age 40, where calcium is rare and event rates are very low
• Symptomatic patients (who need stress testing or coronary CT angiography instead)

The American College of Cardiology also highlights certain "risk-enhancing" conditions that may push a clinician toward ordering the scan: family history of premature coronary disease, South Asian ancestry, chronic inflammatory conditions like rheumatoid arthritis or lupus, and metabolic syndrome [8].

How Percentile Ranking Adds Context

A raw Agatston score of 50 carries different weight in a 45-year-old man than in a 75-year-old woman. That is why CAC results are also reported as a percentile relative to age, sex, and ethnicity, drawn from the MESA database [5].

A patient at the 75th percentile or above has more coronary calcium than 75% of demographically similar individuals. The 2019 ACC/AHA guidelines specifically reference this threshold as a trigger for statin initiation [8]. A 48-year-old man with a CAC of 50 might sit at the 80th percentile, placing him well above average and in the treatment-favored zone. A 72-year-old woman with the same score of 50 might sit at the 30th percentile, which is below average for her age group.

MESA's online CAC calculator (available through the MESA-NHLBI website) allows clinicians to enter age, sex, ethnicity, and Agatston score to retrieve the exact percentile. The Framingham Offspring cohort validated these percentile distributions in a predominantly White population (N=3,529, mean follow-up 8.1 years), confirming the independent prognostic value of age/sex-adjusted CAC [12].

What the Test Cannot Tell You

The CAC score has clear blind spots. It does not detect non-calcified ("soft") plaque, which can still rupture and cause acute coronary syndromes. Young patients with aggressive atherosclerosis may have lipid-rich, inflammatory plaque but a CAC of 0. The SCOT-HEART trial (N=4,146) demonstrated that coronary CT angiography (which uses IV contrast) identifies both calcified and non-calcified stenoses and changed management in 23% of patients with stable chest pain, a population where a non-contrast CAC scan would miss soft obstructive lesions [13].

The score also cannot quantify stenosis. A CAC of 400 might represent diffuse, non-obstructive calcification across multiple vessels, or it might be concentrated in a single artery causing significant narrowing. Only functional testing (stress echocardiography, nuclear perfusion imaging) or anatomic testing (coronary CT angiography, invasive angiography) can distinguish these scenarios.

Serial CAC scanning remains controversial. Statins consistently slow the rate of calcium progression but do not reduce absolute scores, because they stabilize plaque and may even increase calcium density while shrinking the lipid core [14]. A rising CAC on statin therapy does not necessarily mean treatment is failing. For this reason, the ACC does not endorse routine serial CAC testing to monitor treatment response [8].

CAC Score and Statin Decision-Making

The practical value of the test lives in a single clinical scenario: the patient whose traditional risk estimate lands in a gray zone. A 55-year-old woman with an LDL of 145 mg/dL, no diabetes, a systolic blood pressure of 132 mmHg, and a 10-year ASCVD risk of 8.5% sits squarely in the borderline-to-intermediate range. Guidelines recommend shared decision-making about statins.

If her CAC is 0, MESA data suggest her actual 10-year event risk drops well below 5%, making the number-needed-to-treat for statin benefit very high [5]. Many clinicians would defer the statin, recheck risk factors in 3 to 5 years, and consider rescanning in 5 to 10 years.

If her CAC is 150 (above the 75th percentile for a 55-year-old woman), her risk is reclassified upward. The ACC/AHA guidelines favor statin initiation [8]. The MESA Air Study (N=6,654) confirmed that adding CAC to the PCE reclassified 44% of intermediate-risk adults into either low- or high-risk categories, the largest net reclassification improvement of any tested biomarker [15].

The 2023 AHA/ACC Chronic Coronary Disease guideline reinforced this framework, noting that "CAC scoring is reasonable for asymptomatic adults in whom a management decision, such as the institution of preventive pharmacotherapy, remains uncertain after risk assessment" [16].

How to Lower Cardiovascular Risk Once You Know Your Score

A CAC score, once positive, does not go back to zero. Calcium in the artery wall is permanent barring extreme circumstances. The goal is reducing the probability that calcified or adjacent non-calcified plaque causes an event.

Statin therapy is the most evidence-backed intervention. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with elevated hs-CRP but "normal" LDL, a population that overlaps heavily with those who would be identified by CAC screening [17]. MESA follow-up analyses showed that statin-treated patients with high CAC scores had significantly lower event rates than untreated patients with equivalent scores [5].

Beyond statins, the interventions that modify atherosclerosis progression include blood pressure control (the SPRINT trial, N=9,361, showed a 25% reduction in cardiovascular events with a systolic target of 120 mmHg vs. 140 mmHg [18]), smoking cessation, glycemic control in diabetic patients, regular aerobic exercise (150 minutes per week at moderate intensity per AHA guidelines), and dietary patterns emphasizing vegetables, whole grains, nuts, and fish.

Aspirin use in primary prevention has narrowed. The 2019 ACC/AHA guidelines recommend against routine aspirin for adults over 70 or those with bleeding risk, but note that aspirin "might be considered" for select adults aged 40 to 70 at higher ASCVD risk without increased bleeding risk [8]. A high CAC score is one factor that may tilt the decision toward low-dose aspirin in this specific subgroup.

Dr. Khurram Nasir, chief of the Division of Cardiovascular Prevention and Wellness at Houston Methodist, has noted: "The calcium score does not tell you what to eat or how often to exercise. It tells you where you stand on the disease continuum so you and your clinician can match the intensity of prevention to the severity of the problem" [19].

Repeat Testing and Long-Term Monitoring

Current ACC/AHA guidelines do not provide a firm interval for repeat CAC scanning [8]. MESA data suggest that the "warranty" of a zero score lasts approximately 5 years before a meaningful number of previously calcium-free participants develop detectable deposits. After 10 years, roughly 25% of patients with an initial score of 0 will have a positive result on repeat scanning [7].

For patients with a positive baseline CAC, the decision to rescan depends on the clinical question. If the initial score was low (1 to 10) and the patient deferred statin therapy, rescanning in 3 to 5 years can clarify whether calcium is progressing quickly enough to change the treatment decision. If the initial score was already high (above 100) and the patient started treatment, there is little clinical value in repeating the scan. The expected annual increase in CAC among statin-treated patients is 15% to 25%, and as noted above, rising calcium under statin therapy reflects plaque stabilization rather than treatment failure [14].

Insurance coverage varies. Medicare does not cover screening CAC, and most commercial plans also exclude it. The out-of-pocket cost in the United States ranges from $75 to $300, making it one of the most affordable advanced imaging tests available for cardiovascular risk stratification.